On September 24, 2024, Aclarion, Inc. announced the entry into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC to sell shares of its common stock with an aggregate offering price of up to $10 million. The sales will be conducted through an at-the-market offering, subject to the limitations of General Instruction I.B.6 of Form S-3. A prospectus supplement was filed with the SEC for the sale of up to $1,075,000 of common stock under this offering. The shares will be sold pursuant to Aclarion's effective shelf registration statement, which was filed on September 9, 2024, and declared effective by the SEC on September 23, 2024. The Agent will sell the shares based on the company's instructions and within legal and regulatory guidelines. Aclarion will pay a commission of up to 3.0% of the gross proceeds from the sales and reimburse the Agent for certain expenses. Both Aclarion and the Agent have the right to terminate the Sales Agreement at their discretion.

On September 24, 2024, Aclarion, Inc. announced the entry into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC to sell shares of its common stock with an aggregate offering price of up to $10 million. The sales will be conducted through an at-the-market offering, subject to the limitations of General Instruction I.B.6 of Form S-3. A prospectus supplement was filed with the SEC for the sale of up to $1,075,000 of common stock under this offering. The shares will be sold pursuant to Aclarion's effective shelf registration statement, which was filed on September 9, 2024, and declared effective by the SEC on September 23, 2024. The Agent will sell the shares based on the company's instructions and within legal and regulatory guidelines. Aclarion will pay a commission of up to 3.0% of the gross proceeds from the sales and reimburse the Agent for certain expenses. Both Aclarion and the Agent have the right to terminate the Sales Agreement at their discretion.